Olema Q3 Loss Widens to $73.6M; Cash Falls to $413.8M Ahead of Q1 2027 OPERA-01 Data
OLMA sits 18% above its 52-week low of $6.235.
Summary
Olema reported a Q3 2026 net loss of $73.6M, up from $42.2M a year earlier, with $413.8M in cash and marketable securities. Management kept the pivotal OPERA-01 top-line data on track for the first quarter of 2027.
Key Events · Earnings and Guidance · OLMA
-
Q3 Net Loss Widens to $73.6M
Net loss for the quarter ended September 30, 2026 was $73.6M versus $42.2M a year earlier, while GAAP R&D rose to $67.6M from $40.0M on OPERA-01 and OPERA-02 enrollment and manufacturing scale-up.
-
Cash Falls to $413.8M
Cash, cash equivalents and marketable securities stood at $413.8M at September 30, 2026, down from $505.4M at December 31, 2025 — roughly $92M consumed in nine months.
-
OPERA-01 Top-Line Set for Q1 2027
Top-line data from the pivotal Phase 3 OPERA-01 trial remain on track for the first quarter of 2027, management reaffirmed, with OPERA-02 enrollment described as accelerating.
-
OP-3136 Combination Study to Start Q4 2026
Enrollment is expected to begin in the fourth quarter of 2026 for the Phase 1b/2 study of OP-3136 with darolutamide in mCRPC, in collaboration with Bayer.
Analysis · OLMA · Life Sciences
Cash burn stepped up sharply this quarter, with a net loss of $73.6M against $42.2M a year ago as enrollment in both Phase 3 trials and manufacturing build-out weighed on the P&L. Cash of $413.8M is down roughly $92M since December 31, 2025, so the runway now hinges on how fast OPERA-01 and OPERA-02 consume capital before the Q1 2027 top-line readout. That readout is the single event that will define the company's value, and management reaffirmed the timing rather than moving it. The CFO appointment referenced here was already disclosed in the August 13, 2026 8-K, so it is context, not news.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OLMA was trading at $7.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $644M. The 52-week trading range was $6.24 to $36.26. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.